Five Elevated Lipoprotein(a) Levels, Five Different Outcomes

Five patients, different paths, and what to do when your result is high

Nearly fifteen years ago, a man in his late fifties came to see me for medication refills. His regular cardiologist was on vacation. It was supposed to be a short visit, but he had a question that would stay with me.

“Doctor, why did I have a heart attack? I don’t smoke. I exercise. I run marathons. I eat healthy. My cholesterol isn’t very high. I don’t have high blood pressure. I don’t have diabetes. All I have is a family history, and I’ve done everything I can to make up for that.”

He looked defeated. He had done the work, and the outcome seemed to tell him that the work had not mattered.

His question sent us beyond the usual cholesterol panel. The result that changed our conversation was his lipoprotein(a), usually shortened to Lp(a) and pronounced “L-P-little-a”: 245 mg/dL.

That result helped explain an inherited risk his running could not remove. It did not prove that Lp(a) alone caused his heart attack, or that his healthy habits had failed him.¹

Four more patients would deepen that lesson. One needed coronary stents at 45. Another reached 78 with a calcium score of zero. A welder sought a check-up at the age his father had died and discovered serious disease without symptoms. A travel agent had already been through repeated stent and bypass-graft closures.

Five elevated results. Five very different clinical courses. The number mattered in every story, but it did not finish any of them.

These clinical stories are shared for education, with identifying details omitted. They are not individual medical advice.

The runner: an explanation, not a verdict

The runner’s Lp(a) was not a small abnormality. It was a substantial inherited risk that needed to be considered alongside his family history and the heart attack he had already experienced.¹

Here is the biology you need for this discussion: Lp(a) is a mostly inherited cholesterol-carrying particle, and a high level increases cardiovascular risk.¹ Healthy eating and exercise generally do not substantially lower the level itself, but they remain part of cardiovascular prevention.¹

The practical question was not how to make him exercise harder. It was what protection still needed to be added to the effort he was already making.

Later, this patient took niacin and added fish to his diet. His repeat Lp(a) was around 120 mg/dL. At the time, we counted the lower number as a win. Looking back, that observation could not tell us which part of the change came from treatment, or whether it translated into fewer future events.

His first question was about why the heart attack happened. The next question was what would actually help him avoid another one. Those questions overlap, but they are not interchangeable.

The number does not tell us everything about the particle

Lp(a) is not one uniform particle. Its attached protein, apolipoprotein(a), or apo(a), comes in different inherited sizes. These variants, called isoforms, make Lp(a) structurally heterogeneous: the label describes a family, not identical copies.²

Smaller apo(a) forms often accompany higher Lp(a) concentrations.¹ Human-genetic research also suggests that size can influence coronary risk beyond concentration, but it does not establish the benefit of routine size testing.³

A standard Lp(a) result reports concentration, not a structural profile. A result in mg/dL reports mass, not particle number; similar mass results can represent different particle counts because the particles differ in size.² Some assays can also under- or overestimate results depending on apo(a) size.²

Reporting in nmol/L better represents particle concentration, ideally using a validated assay that minimizes size-related bias.¹ It still does not identify your isoforms, and no universal formula reliably converts between the units.²

That does not make an mg/dL result useless. Guidance considers accurate concentration measurement sufficient for routine Lp(a)-related risk assessment, without specialized isoform testing.¹ Current U.S. risk-enhancing thresholds are at least 50 mg/dL or 125 nmol/L, not an exact conversion between units.⁴

For these five patients, we have concentrations, not isoform measurements. We cannot claim that particle size explains their different outcomes. The practical step is to read the units, check the measurement method when needed, and interpret the result alongside the rest of the cardiovascular picture.¹

The 45-year-old: inherited risk with additional fuel

Another patient was 45 when he developed unstable angina, an acute coronary syndrome. Cardiac catheterization showed multivessel disease, and he underwent staged stenting of all three major coronary arteries.

His Lp(a) was 178 nmol/L. His father and uncles had suffered heart attacks in their forties and fifties. He also smoked and ate a poor-quality diet.

Here, the conventional risks were not absent. The family history and Lp(a) added to them. It would have been a mistake to discover the inherited particle and then treat smoking or the rest of his prevention plan as secondary concerns.¹,⁵

It would have been equally incomplete to say that smoking explained everything, so there was no reason to ask about inherited risk. His relatives’ early disease was part of the history, not background noise.

Once someone has coronary disease, prevention is no longer only about estimating the chance of a first event. It is about preventing the next event, with lipid lowering, smoking cessation, appropriate antiplatelet treatment, activity, nutrition, and management of other risks working together.⁵

A stent treats a particular narrowing; it does not remove the underlying tendency to develop atherosclerosis elsewhere.⁵ That is why the prevention conversation must continue after the procedure.

The runner’s story challenged the assumption that healthy habits guarantee protection. This patient’s story challenged the opposite assumption: that an inherited risk makes the habits we can change irrelevant.

The 78-year-old: a high result and a reassuring scan

Then there was the woman who keeps me humble. At 78, she had a strong family history of heart disease and a history of LDL cholesterol at 190 mg/dL.

After news coverage of Lp(a) treatments in development, her primary-care physician checked her level. It was 180 nmol/L, close to the 45-year-old’s result in the same units.

Her coronary calcium score was zero. Her exercise nuclear stress test showed excellent exercise tolerance and no inducible ischemia.

The contrast is the reason to tell these stories together. One person had required multivessel stenting at 45. Another, more than three decades older, had no detectable coronary calcium. Their Lp(a) values alone could not account for that difference.

Her findings were reassuring, not proof that her arteries contained no plaque: calcium scoring does not exclude noncalcified plaque, and a normal stress test does not establish plaque-free arteries.⁴,⁵ Her previous LDL of 190 still deserved attention rather than dismissal because the scan was reassuring.⁴

An observational analysis of MESA and the Dallas Heart Study found the highest risk when elevated Lp(a) accompanied substantial coronary calcium; with CAC zero, elevated Lp(a) did not identify a statistically significant increase in events during the reported follow-up.⁶ That supports putting the tests together, not promising that a zero erases lifetime risk.

She had never smoked. She also wanted her story to include gratitude, a positive outlook, and the ownership she had taken of her health. I wanted to honor that without claiming that positive thinking had prevented coronary disease.

Her result did not require us to manufacture an emergency. It required a proportionate conversation about what was reassuring, what remained relevant, and what prevention made sense at her age.

The welder: 52 was not just an age

For the welder, 52 had a particular meaning. His father had died at 52. When he reached that age himself, he came for a check-up because of that family history.

He was asymptomatic. He did not smoke, tried to eat healthfully, and had made an effort to take care of himself. His Lp(a) was 257 mg/dL.

His calcium score was in the 400s. A stress test was abnormal. Catheterization showed multivessel coronary disease involving the left main, and he was referred for coronary artery bypass surgery.

The important contrast was not simply between two laboratory values. The runner had already had a heart attack. The welder had serious disease discovered before a symptomatic event brought him to care.

I reassured him that his efforts had not been pointless. Perhaps, without them, his course would have been worse. But I could not tell him that his habits were the reason he had survived to 52, or promise that he otherwise would have shared his father’s fate.

What we did know was more useful: he had acted on his family history, and we had identified disease that changed his care. The next step was evaluation for bypass surgery.

There is a difficult emotional trap in prevention. A person can work hard and still develop disease, then interpret the diagnosis as evidence that the work failed. The runner had felt it. The welder’s experience raised the same question in a different form.

The answer cannot be a guarantee. It is that inherited risk and modifiable risk coexist, and addressing the second remains worthwhile even when the first is substantial.¹ Discovering advanced disease does not turn years of not smoking into a wasted effort.

Nor does his case mean that everyone with high Lp(a) needs a stress test or catheterization; testing decisions depend on the whole clinical picture, not this blood result alone.⁴,⁵

The travel agent: when the usual explanation was not enough

The fifth patient was a 55-year-old travel agent with an unusually aggressive course: coronary stents, stent closure, bypass surgery, bypass-graft occlusions, stents in the grafts, and then closure of those stents.

This was precisely the kind of patient in whom I looked beyond the standard risk factors. Not because the usual risks had disappeared, but because the extent and recurrence of disease demanded a broader look.

LDL readings were in the 170–180 range, and HDL had generally been in the 20s and 30s. Lp(a) was in the 190s mg/dL. Homocysteine was elevated, and testing identified two copies of the common MTHFR C677T variant.

This was before the AIM-HIGH trial changed how we viewed niacin. The regimen included rosuvastatin, ezetimibe, and niacin at 2,000 mg, with aspirin and an apple before the niacin. This is a historical account of supervised care, not a regimen for readers to reproduce.

Food was part of the prescription too: a daily blended salad of two handfuls of mixed greens, a cup of red grapes, a tablespoon of freshly ground flax seeds, and pomegranate juice. We also used methylfolate, vitamin B6, and vitamin B12.

Over three to six months, Lp(a) fell approximately 20–25%, homocysteine fell from 19 to 10, and HDL rose from 32 to 48. The patient remained angina-free for three to four years before being lost to follow-up.

That symptom-free interval mattered. It does not establish that the grafts stayed open, that no cardiovascular events occurred, or that any single ingredient in the plan caused the improvement. Several treatments changed together.

Later, AIM-HIGH found no incremental cardiovascular benefit from adding niacin to statin therapy.⁷ HPS2-THRIVE likewise found no significant major vascular-event benefit from niacin plus laropiprant and identified more serious adverse effects.⁸

Neither trial specifically selected patients for elevated Lp(a), but the results do not support reviving routine niacin treatment to chase an Lp(a) or HDL number.¹ The lesson I retain is the need to look broadly and treat comprehensively, not to turn an old regimen into a modern promise.

Why homocysteine belonged in that conversation

Before the newer broad Lp(a) testing recommendations, I did not screen all comers indiscriminately. I looked especially at people with family histories of premature coronary disease, personal histories of premature disease, failure of conventional therapy, coronary or peripheral or cerebrovascular disease, and recurrent cardiovascular events.

The recurring question was whether the amount or behavior of vascular disease was adequately explained by the standard risk factors. Lp(a) and, selectively, homocysteine were part of that expanded search.

An elevated homocysteine result raises questions about folate and B12 status, kidney function, and other contributors; it is not a specific diagnosis of a genetic processing problem.⁹ My food inventory asks a practical question: is this person regularly eating folate-rich foods, particularly leafy greens, rather than relying on fortified products?

When supplementation is appropriate, I prefer methylfolate and consider B12 and B6 alongside it. I sometimes consider MTHFR testing, although the result often does not change my plan; routine testing for common variants is generally not needed to guide care.¹⁰

Two copies of C677T do not establish why a particular stent or graft closed.¹⁰ My preference for methylfolate is a clinical choice, not proof of better cardiovascular outcomes.

B12 status needs attention before substantial folate supplementation, which can conceal the anemia of B12 deficiency without treating its neurological effects.¹¹ The practical step is to review food intake, possible deficiencies, and the reason for the elevated result rather than buying a supplement stack.

Most importantly, lowering homocysteine is not the same as proving fewer heart attacks: randomized B-vitamin trials have not established reductions in myocardial infarction or mortality, although a major pooled review found a small stroke reduction.¹² Excessive long-term B6 can also injure nerves.¹³

The travel agent’s response belongs in the story as an observation. It is not permission to substitute supplements for established coronary treatment.

Prevention and lowering Lp(a) are not the same decision

The 2026 ACC/AHA guideline recommends measuring Lp(a) at least once in adulthood, a broader approach than my earlier selective testing.⁴ That recommendation does not mean ordering every other proposed cardiovascular marker in everyone.

Three decisions need to remain separate: whether to measure Lp(a), whether its result should strengthen the prevention plan, and whether to prescribe a treatment specifically to lower Lp(a). Broader screening does not automatically establish a drug indication for each person with an elevated result.¹,⁴

There is good reason to take the rest of the risk profile seriously. In an observational MESA analysis, more favorable cardiovascular health was associated with lower event risk even among people with high Lp(a), although it did not eliminate the inherited risk.¹⁴ The study supports that direction of care; it is not a randomized promise about what a particular lifestyle change will accomplish.

Better prevention improves the odds. It does not give us complete control, and it does not make a heart attack a verdict on someone’s discipline.

The drug question requires its own evidence. On September 4, 2026, Novartis announced that pelacarsen’s Lp(a)HORIZON trial had not met its primary cardiovascular endpoint despite lowering Lp(a).¹⁵ In its September statement, the National Lipid Association noted that full clinical results were not yet available and continued to recommend Lp(a) testing and intensive management of other risks.¹⁶

These five cases cannot explain why that trial missed its endpoint. Nor does that topline result justify treating Lp(a) as irrelevant or assuming that every future approach will have the same result. It reminds us why a laboratory response and an outcome benefit must be tested separately.

What none of the five results could tell me

None could show how much narrowing was present. None could tell me whether the next decade would resemble the 45-year-old’s course or the 78-year-old’s. None could identify the cause of every recurrent closure in the travel agent.

The result belongs beside the history, symptoms, standard lipid measurements, blood pressure, glucose, and evidence of vascular disease, not above them.¹,⁴ Treatment should reflect that complete picture.

For someone with established coronary disease, that can mean substantial LDL lowering with a statin and additional medicines when needed, alongside nutrition, movement, smoking cessation, and other proven care.⁵ For someone without known disease, the discussion includes absolute risk, treatment benefit and burden, and whether further assessment would change the plan.⁴

That is the difference between a frightening result and a useful one. A useful result changes a decision, clarifies a priority, or tells us what question to ask next.

What to do with your result

You do not need to master the chemistry before taking the next step. Bring the actual report, your medication list, and the ages at which close relatives developed heart or vascular disease. Then work through a few concrete questions with your clinician.

Find out which prevention conversation you are having

Ask: “Are we trying to prevent a first event, or do I already have disease that requires treatment?” Prior heart attack, coronary stenting or bypass, and other established atherosclerotic disease change the treatment conversation substantially.⁴,⁵

The runner and travel agent did not need another risk marker to prove that prevention mattered. They already had coronary disease. The 78-year-old needed a different conversation, one that respected her reassuring tests without ignoring her history.

If further testing is proposed, ask what decision the result would change. A high Lp(a) result alone is not an instruction to collect scans or proceed to catheterization.⁴,⁵

Get a specific cholesterol plan

Ask: “What should my LDL cholesterol goal be, and am I there?” Elevated Lp(a) supports more intensive attention to LDL, but the goal and choice of medicines still depend on the person’s overall risk and treatment tolerance.⁴

For people with established cardiovascular disease at very high risk, current guidance generally recommends LDL-C below 55 mg/dL; that is not an automatic target for every otherwise healthy person with an elevated Lp(a).⁴ Ask how the proposed target was chosen for you.

Also ask when to repeat the standard lipid panel and how the plan will change if the response is inadequate. “Watch your cholesterol” is not as useful as a target, a treatment decision, and a follow-up date.

Put the daily work beside the prescription

Food and medication are not competing loyalties. A heart-healthy eating pattern, regular physical activity, avoiding tobacco, and appropriate control of blood pressure and diabetes belong alongside indicated medicines, not in place of them.⁵

Make food changes concrete: build more meals around vegetables, beans, whole grains, nuts, and other minimally processed foods, with fish when appropriate.⁵ The blended salad was one way of making food part of the travel agent’s routine; it was not a special antidote to Lp(a).

If you smoke, ask for a cessation plan rather than relying on willpower alone; if you have coronary disease, ask what activity is safe and whether cardiac rehabilitation is appropriate.⁵ Discuss blood-pressure and glucose goals when relevant, and identify the change you can realistically sustain.

The task is not to perform health perfectly. It is to make the next meal, the next week, and the next follow-up part of the same workable plan.

Let the information help your family

Ask whether parents, siblings, and children should be tested, with childhood testing discussed with the child’s clinician.⁴ Share the result and its units rather than telling relatives they are destined to have your outcome.

The welder acted because his father’s age at death mattered to him. Family information is most useful when it leads to timely assessment, not when it becomes a prediction everyone carries in silence.

Do not chase the number on your own

Do not start niacin, aspirin, or high-dose vitamins simply because the Lp(a) result is elevated; each has separate indications, limitations, or risks.¹,⁵,¹³ Ask what benefit is expected from any proposed treatment and what will be monitored for safety.

Ask for a follow-up plan that tracks what you are actually treating. The visit should not end with an isolated abnormal result and a vague instruction to worry less.

Before you close this

I still return to the runner’s question. He wanted an explanation, but he also needed to know that his effort had not been meaningless.

The answer is neither that genes decide everything nor that perfect habits can control everything. The inherited particle is one part of the story. The purpose of finding it is to build a better plan around the person who carries it.

---

This article is for general education and does not replace individualized medical advice. Do not start, stop, or change medication or supplements without discussing your circumstances with your clinician.

References

1. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925–3946. Full article and DOI.

2. Marcovina SM, Albers JJ. Lipoprotein(a) measurements for clinical application. J Lipid Res. 2016;57(4):526–537. doi:10.1194/jlr.R061648. Full article.

3. Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5(7):524–533. doi:10.1016/S2213-8587(17)30088-8. Full article.

4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. doi:10.1016/j.jacc.2025.11.016. Guideline.

5. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023. doi:10.1161/CIR.0000000000001168. Guideline.

6. Mehta A, Vasquez N, Ayers CR, et al. Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk. J Am Coll Cardiol. 2022;79:757–768. PubMed record.

7. AIM-HIGH Investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med. 2011;365:2255–2267. Trial.

8. HPS2-THRIVE Collaborative Group. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. N Engl J Med. 2014;371:203–212. Trial.

9. Bedz D, Forsyth C. Vitamin B12 deficiency: testing and treatment. Aust Prescr. 2026;49(2):55–60. doi:10.18773/austprescr.2026.012. Full article.

10. MedlinePlus. MTHFR Gene Test. Patient resource.

11. National Institutes of Health, Office of Dietary Supplements. Folate: Fact Sheet for Health Professionals. Folate guidance.

12. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8:CD006612. Systematic review.

13. National Institutes of Health, Office of Dietary Supplements. Vitamin B6: Fact Sheet for Health Professionals. Vitamin B6 safety guidance.

14. Razavi AC, Reyes MP, Wilkins JT, et al. Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a). Eur J Prev Cardiol. Published online November 28, 2024. Full article.

15. Novartis. Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease. September 4, 2026. Sponsor announcement.

16. National Lipid Association. Top Line Results from the Phase 3 Lp(a)HORIZON Trial. September 16, 2026. Professional society statement.